Trial Profile

A Phase I Study to Compare the Pharmacokinetic Characteristics, Safety, Tolerability, and Immunogenicity (Randomized, Double-blind, Parallel Controlled) of HLX15 With Daratumumab Injection in Healthy Chinese Male Subjects

Status: Completed

Phase of Trial: Phase I

Latest Information Update: 15 Jul 2024

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

28 Jun 2024 Primary endpoint has been met (Area under the serum concentration-time curve from time 0 to infinity (AUC0-inf) , according to a Shanghai Henlius Biotech Inc. media release
28 Jun 2024 Status changed to completed, according to a Shanghai Henlius Biotech Inc. media release
28 Jun 2024 Results published in a Shanghai Henlius Biotech Inc. media release

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com